Merck & Co. has entered into a definitive agreement to acquire Terns Pharmaceuticals for an approximate total equity value of $6.7 billion, a strategic move designed to fortify its oncology portfolio and secure a potential blockbuster treatment for chronic myeloid leukemia (CML). Announced on Wednesday, the deal centers on Terns’ lead drug candidate, TERN-701, an oral small-molecule tyrosine kinase inhibitor (TKI) that industry analysts believe could eventually outperform existing therapies from competitors like Novartis. The acquisition represents a significant step in Merck’s broader effort to diversify its revenue streams ahead of the late-decade patent expiration of its flagship immunotherapy, Keytruda.
Under the terms of the agreement, Merck will pay $53.00 per share in cash for all outstanding shares of Terns Pharmaceuticals. While this price represents a modest 6% premium over Terns’ closing price on the Tuesday preceding the announcement, it reflects a more substantial 31% premium over the 60-day volume-weighted average price and a 42% premium over the 90-day average. When accounting for the cash currently held on Terns’ balance sheet, the net enterprise value of the transaction is estimated at approximately $5.7 billion.
Strategic Significance and the TERN-701 Asset
The centerpiece of the acquisition, TERN-701, is currently in clinical development for the treatment of chronic myeloid leukemia. CML is a slow-growing form of blood cancer that originates in the bone marrow and is characterized by the overproduction of white blood cells. Specifically, TERN-701 targets patients with Philadelphia chromosome-positive (Ph+) CML in the chronic phase.
The Philadelphia chromosome is a genetic abnormality that results from a reciprocal translocation between chromosomes 9 and 22, leading to the formation of the BCR-ABL1 fusion gene. This gene produces a protein that triggers the uncontrolled growth of leukemic cells. While the advent of first-generation TKIs like imatinib (Gleevec) revolutionized CML treatment, many patients eventually develop resistance or intolerance to these early therapies. TERN-701 belongs to a newer class of allosteric inhibitors that bind to the ABL myristoyl pocket, a distinct site from the traditional ATP-binding site targeted by older drugs. This mechanism allows the drug to remain effective even in cases where mutations have rendered other TKIs obsolete.
A Comparative Advantage: TERN-701 versus Scemblix
Merck’s acquisition is a direct challenge to Novartis, which currently dominates the allosteric CML inhibitor market with its drug Scemblix (asciminib). Scemblix received accelerated FDA approval in 2021 and has since become a cornerstone of Novartis’s oncology revenue, generating nearly $1.3 billion in global sales in 2025—a staggering 87% increase year-over-year.
However, clinical data suggests that TERN-701 may offer several "best-in-class" advantages over Scemblix. During the American Society of Hematology (ASH) annual meeting in December, Terns Pharmaceuticals presented Phase 1 data from its CARDINAL study, which demonstrated high rates of major molecular response (MMR) in heavily pre-treated patients.
Beyond efficacy, the primary differentiators are patient convenience and pharmacokinetics. Scemblix requires twice-daily dosing and carries strict dietary restrictions, requiring patients to fast for two hours before and one hour after taking the medication. In contrast, TERN-701 is designed as a once-daily pill that can be taken with or without food. In the world of chronic cancer care, where adherence is critical to preventing disease progression, these lifestyle advantages can lead to significant market share gains.
The "Keytruda Cliff" and Merck’s M&A Strategy
The acquisition of Terns Pharmaceuticals is the latest in a series of high-profile moves by Merck to mitigate the impact of the impending "patent cliff" for Keytruda. As the world’s top-selling cancer drug, Keytruda accounts for a massive portion of Merck’s annual revenue. However, its primary patents are set to expire toward the end of the 2020s, potentially exposing the company to a sharp decline in earnings as biosimilars enter the market.
Merck CEO Robert Davis has been aggressive in deploying capital to acquire "de-risked" clinical assets that can provide growth in the 2030s. Within the past year alone, Merck has committed $9.2 billion to acquire influenza drug developer Cidara Therapeutics and $10 billion for Verona Pharma, which specializes in respiratory treatments like Ohtuvayre for COPD.
"This transaction further diversifies and strengthens our position in oncology as we continue to look for opportunities to broaden our portfolio into other therapeutic areas," Davis said in a statement accompanying the announcement. "The acquisition of Terns Pharmaceuticals and the addition of TERN-701 to our pipeline builds on our growing presence in hematology with a potential best-in-class CML drug."
Financial Terms and Market Reactions
The financial structure of the deal includes a $235 million termination fee that Terns would be required to pay Merck should it accept a superior proposal from another bidder. This "breakup fee" is a standard protection in large-scale pharmaceutical acquisitions, though some analysts suggest the door remains slightly ajar for a bidding war.
Andrew Berens, an analyst at Leerink Partners, noted that the $53-per-share price might "vastly underestimate" the long-term value of TERN-701. Leerink has set a price target of $58 for Terns shares, suggesting that some institutional investors might push for a higher valuation before the tender offer is completed. Berens pointed out that Merck likely gained access to updated Phase 1 data prior to the bid, which reinforced the drug’s superior profile.
William Blair analyst Andy Hsieh echoed this sentiment, stating that TERN-701 has demonstrated "unequivocal improvement in both safety and efficacy." Hsieh believes the drug is positioned to "disrupt the treatment paradigm of CML" and could realistically challenge Scemblix’s dominance in both late-line and early-line settings.
The Evolution of CML Treatment Paradigms
To understand the impact of TERN-701, one must look at the historical trajectory of CML therapy. For decades, CML was a death sentence, with bone marrow transplants being the only hope for a cure. The introduction of imatinib in 2001 turned CML into a manageable chronic condition for many. However, the "Achilles’ heel" of first- and second-generation TKIs (such as dasatinib and nilotinib) has always been the emergence of gatekeeper mutations, most notably the T315I mutation, which prevents these drugs from binding to the cancer protein.
The shift toward allosteric inhibitors like TERN-701 represents the "third wave" of CML innovation. By targeting the myristoyl pocket, these drugs bypass the mutations that occur at the ATP-binding site. If Merck can successfully move TERN-701 into first-line treatment—meaning it is the first drug a patient receives upon diagnosis—the commercial potential expands exponentially. Currently, Scemblix is gaining traction in earlier lines of therapy in the U.S. and Japan, and Merck’s goal will be to prove that TERN-701 is the superior choice for newly diagnosed patients.
Analyst Forecasts and Future Projections
The long-term financial outlook for TERN-701 is robust. Leerink Partners projects that if the drug maintains its current clinical trajectory, it could achieve blockbuster status (exceeding $1 billion in annual sales) by 2032. Looking further ahead, the bank estimates peak sales could reach approximately $6.2 billion by 2040.
These projections are predicated on the drug’s ability to capture a significant portion of the second-line and first-line CML markets. As the population of CML survivors grows due to improved treatments, the total addressable market continues to expand. Merck’s global commercial infrastructure—spanning regulatory affairs, marketing, and distribution—is expected to accelerate TERN-701’s market penetration far more effectively than Terns Pharmaceuticals could have achieved as a standalone biotech company.
Transaction Logistics and Potential Hurdles
The acquisition is structured as a tender offer for Terns’ outstanding shares. It is subject to customary closing conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and the tender of a majority of Terns’ shares. Both companies have stated they expect the transaction to close in the second quarter of this year.
Antitrust scrutiny is a potential, albeit unlikely, hurdle. While the Federal Trade Commission (FTC) has become more aggressive in reviewing pharmaceutical mergers, Merck does not currently have a dominant position in the specific niche of allosteric CML inhibitors. The deal is generally viewed as pro-competitive, as it brings a new challenger to a market currently dominated by Novartis.
Conclusion and Broader Impact
The Merck-Terns deal serves as a bellwether for the current state of the biopharmaceutical industry. As large-cap "Big Pharma" companies face the dual pressures of patent expirations and the Inflation Reduction Act’s drug pricing provisions, they are increasingly turning to targeted acquisitions of high-value, specialized assets.
For Terns Pharmaceuticals, the deal validates years of research into allosteric inhibition and provides the capital necessary to bring TERN-701 through the expensive Phase 3 clinical trial process. For Merck, the $6.7 billion investment is a calculated bet that a better-designed molecule can unseat an established incumbent. If TERN-701 fulfills its promise of becoming the "best-in-class" therapy for CML, Merck will have secured a vital pillar for its post-Keytruda future, ensuring its continued leadership in the global oncology market for decades to come.
